A Multicenter, Open-label, Single-arm, Study of Enzalutamide Re-Treatment in Metastatic Castration-Resistant Prostate Cancer, As First Treatment Post-Chemotherapy in Patients Who Have Previously Received Enzalutamide in the Pre-Chemotherapy Setting
Phase of Trial: Phase IV
Latest Information Update: 25 Apr 2018
At a glance
- Drugs Enzalutamide (Primary) ; Cabazitaxel; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Astellas Pharma; Medivation
- 10 Jun 2017 Biomarkers information updated
- 22 May 2017 Status changed from active, no longer recruiting to discontinued due to feasibility reasons.
- 20 Mar 2017 Planned End Date changed from 1 Nov 2018 to 1 May 2017.